Genotype and clinical characteristics of congenital long QT syndrome in Thailand. by Saprungruang, A. et al.
lable at ScienceDirect
Indian Pacing and Electrophysiology Journal 18 (2018) 165e171Contents lists avaiIndian Pacing and Electrophysiology Journal
journal homepage: www.elsevier .com/locate/ IPEJGenotype and clinical characteristics of congenital long QT syndrome
in Thailand
Ankavipar Saprungruang a, *, Apichai Khongphatthanayothin a, b,
John Mauleekoonphairoj c, Pharawee Wandee c, Supaluck Kanjanauthai d,
Zahurul A. Bhuiyan e, Arthur A.M. Wilde f, Yong Poovorawan a, c
a Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
b Bangkok General Hospital, Bangkok, Thailand
c Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
d Division of Cardiology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand
e Laboratoire de Genetique Moleculaire, Service de Genetique Medicale, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
f Academic Medical Center, Heart Centre, Department of Clinical and Experimental Cardiology, University of Amsterdam, the Netherlandsa r t i c l e i n f o
Article history:
Received 30 April 2018
Received in revised form
7 July 2018
Accepted 19 July 2018
Available online 20 July 2018
Keywords:
Long QT syndrome
Genetics
Mutation
Thailand
Children* Corresponding author. Division of cardiology, De
Chulalongkorn Memorial Hospital, 1873 Rama IV Rd.
Thailand.
E-mail address: ankavipar.s@gmail.com (A. Saprun
Peer review under responsibility of Indian Heart
https://doi.org/10.1016/j.ipej.2018.07.007
0972-6292/Copyright © 2018, Indian Heart Rhythm S
creativecommons.org/licenses/by-nc-nd/4.0/).a b s t r a c t
Background: Congenital long QT syndrome (LQTS) is an inheritable arrhythmic disorder which is linked
to at least 17 genes. The clinical characteristics and genetic mutations may be variable among different
population groups and they have not yet been studied in Thai population.
Methods: Clinical characteristics were retrospectively reviewed from children and young adults with
congenital long QT syndrome whose blood samples were sent for genotyping during 1998e2017. Sangers
sequencing was used to sequentially identify KCNQ1 or KCNH2 genetic variants. Whole exome
sequencing (WES) was used to identify variants in all other known LQTS genes.
Results: Of the 20 subjects (17 families), 45% were male, mean QTc was 550.3 ± 68.8msec (range 470
e731 msec) and total Schwartz's score was 5.6 ± 1.2 points (range 3e8 points). Fifty percent of patients
had events at rest, 30% had symptoms after adrenergic mediated events, and 20% were asymptomatic.
We discovered pathogenic and likely pathogenic genetic variants in KCNQ1, KCNH2, and SCN5A in 6 (35%),
4 (24%), and 2 (12%) families, respectively. One additional patient had variance of unknown signiﬁcance
(VUS) in KCNH2 and another one in ANK2. No pathogenic genetic variant was found in 3 patients (18%).
Most patients received beta-blocker and 9 (45%) had ICD implanted. LQT1 patients were either
asymptomatic or had stress-induced arrhythmia. Most of the LQT2 and LQT3 patients developed
symptoms at rest or during sleep.
Conclusions: Our patients with LQTS were mostly symptomatic at presentation. The genetic mutations
were predominantly in LQT1, LQT2, and LQT3 genes.
Copyright © 2018, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Congenital long QT syndrome (LQTS) is an inheritable cardiac
arrhythmia disorder characterized by prolonged QT interval on
surface ECG, ventricular arrhythmia and sudden cardiac death.
Abnormal ventricular repolarization in these patients predisposespartment of Pediatrics, King
, Patumwan, Bangkok, 10330,
gruang).
Rhythm Society.
ociety. Production and hosting bythem to malignant cardiac arrhythmia such as torsades de pointes
and ventricular ﬁbrillation. The prevalence of long QT syndrome is
thought to be as high as 1 in 2500 population [1], the ﬁgure which
many believed to be underestimated [2].
Currently, at least 17 genes were linked to LQTS [3,4]. Seventy-
ﬁve percent of the patients possess pathogenic mutation in one
of the three genes: KCNQ1, KCNH2, SCN5A [5]. Those with mutation
in each of these particular gene have different clinical character-
istics and are associated with different triggering events for
arrhythmia as well as response to treatment [6]. Therewere reports
on various gene mutation frequency in Asian countries [7e12].
From a previous study in Thai children, the ratio of LQTS patientsElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Clinical characteristics of all Long QT syndrome patients (N¼ 20).
Total (N¼ 20) N %
Male 9 45
Age at Diagnosis (years) Mean (±SD) 7.8 (±6.2)
Range 0e28
Congenital anomalies 3 15
Double aortic arch 1 5
SNHL 2 10
Family history
Deﬁnite LQTS 5 25
SCD 7 35
SNHL 2 10
Total Schwartz's score (points) Mean (±SD) 5.6 (±1.2)
Range 3e8
Electrocardiographic characteristics
Torsade de pointes 4 20
T wave alternans 1 5
Notched T wave 10 50
Bradycardia for age 5 25
QTc (msec) Mean (±SD) 550.3 (±68.8)
Range 470e731
Treatments
Beta blocker 19 95
ICD 9 45
Current Status
Alive 19 95
Death 1 5
SNHL¼ sensorineural hearing loss, LQTS¼ Long QT syndrome, SCD¼ sudden car-
diac death, QTc¼ corrected QT interval, msec¼millisecond, bpm¼ beat per minute,
HR¼ heart rate, ICD¼ implantable cardioverter-deﬁbrillator.
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those found in other Asian countries [13]. However, genetic testing
results was not previously examined in Thai population.
Our study aimed to review the clinical characteristics and ge-
netic mutation of LQTS in Thai patients diagnosed between 1998
and 2017.
2. Materials and methods
The study population included all patients diagnosed with
congenital long QT syndrome in whom DNA sample were available
from January 1st, 1998 to June 30th, 2017. Outpatient and inpatient
medical records of the children and young adults with the diag-
nosis of long QT syndrome were reviewed from the database of
samples that were sent to King Chulalongkorn Memorial Hospital
for LQTS genotyping. The study has been approved by the Ethics
Committee of the Faculty of Medicine, Chulalongkorn University.
Written informed consents were mandatorily obtained from all
patients and/or their guardians.
2.1. Data collection
Demographic data, family history, clinical presentation, echo-
cardiogram ﬁndings and others special cardiac investigations,
treatments and outcomes were collected.
2.2. Diagnosis
The diagnosis of congenital long QT syndrome was made in
accordance to the 2013 HRS/EHRS/APHRS Consensus Guideline
(HRS/EHRS/APHRS consensus) [14]. Only patients with congenital
LQTS were recruited. Those with QTc interval prolongation from
other identiﬁable causes were excluded. QT interval was measured
in lead II or V5 and corrected for differences in heart rate by Bazett's
formula.
2.3. Blood samples collection and DNA extraction
Blood samples (EDTA) were collected from every patient and
their family members after informed consents were obtained.
Genomic DNA was isolated from peripheral white blood cells
through phenol/chloroform extraction.
2.4. Mutation analysis
Sequential screenings of genetic variants in KCNQ1 and KCNH2
were ﬁrst done through PCR ampliﬁcation and Sangers sequencing
according to patient's clinical characteristics. If pathogenic muta-
tion was not found in these 2 genes, the other genes were then
examined with whole exome sequencing (WES). Primers used in
PCR ampliﬁcation were located in the intronic region to cover all
exons of KCNQ1 and KCNH2 genes. The amplicons were visualized
on 2% agarose gel, excised and puriﬁed. Puriﬁed DNA was
sequenced at 1st BASE Laboratories, Selangor Darul Ehsan,
Malaysia. All sequences were aligned with their reference gene
obtained from GenBank, under accession numbers NM_000218
(KCNQ1) and NM_000238 (KCNH2), through sequencer software
package (Gene Codes Corporation, Ann Arbor, Michigan, USA).
2.5. Whole exome sequencing
Genomic DNA samples were sent to Macrogen, Inc. (Seoul, Ko-
rea) for whole exome sequencing. DNA samples were enriched by
SureSelect Human All Exon V5 (Agilent Technologies, Santa Clara,
Calif., USA) and were sequenced onto Hiseq 4000 (Illumina). Theraw data per exome were mapped to the human reference genome
hg19 using BWA. Variant calling was performed using GATK with
HaplotypeCaller. Finally, SNVs and Indels were annotated by using
SnpEff and annotation database that were dbpSNP 142, 1000
Genome, ClinVar and ESP.
Analysis of protein coding and ﬂanking regions of the following
genes was done: KCNQ1, KCNH2, SCN5A, ANK2, KCNE1, KCNE2,
KCNJ2, CACNA1C, CAV3, SCN4B, AKAP9, SNTA1, KCNJ5, CALM1, CALM2,
CALM3, TRDN. Filtering for possible pathogenic mutations (rare
variants) were done by the following criteria: 1) Non-synonymous
variants in either protein coding regions or splice sites, and 2)
Minor allele frequency (MAF) of <0.1% on 1000 Genome project
(http://www.1000genomes.org). Rare variants previously reported
to be the cause of LQTS were classiﬁed as pathogenic. Rare variants
with no previous report of pathogenicity were further classiﬁed as
likely pathogenic, likely benign and variants of unknown signiﬁ-
cance (VUS) based on the American College of Medical Genetics and
Genomics (ACMG) and Association of Molecular Pathology (AMP)
2015 guideline [15]. Only plausible pathogenic or pathogenic vari-
ants are reported as the cause of LQTS in this cohort. We also
conﬁrmed the MAF of all likely pathogenic and pathogenic variants
against our in-house exome sequencing data (719 samples at the
time of the study).
2.6. Statistical analysis
Continuous data are expressed as mean± SD and nominal data
are expressed as percentage.
3. Results
3.1. Clinical characteristic
A total of 30 patients in 27 families diagnosed with congenital
long QT syndrome were identiﬁed. Due to deaths and losses to
follow up, only 20 patients from 17 families were available for
Table 2
Phenotypes and genotype of the patients (N¼ 20).
No. Age at
diagnosis
Schwartz's
score
Longest QTc
(msec)
Trigger events Rare Variants: Molecular consequence Clinical
signiﬁcant
KCNQ1 mutation (N¼ 7)
1a 1 day 4.5 515 Asymptomatic, bradycardia for
age
(exon7) c.1032 G> C (p.Ala344¼)b missense variant Pathogenic
2 4.1 years 4.5 573 Asymptomatic, family
screening
(exon7) c.1032 G> C (p.Ala344¼)b missense variant Pathogenic
3a 9.3 years 5 554 Exercise (exon7) c.1032 G> C (p.Ala344¼)b missense variant Pathogenic
4a 0.2 years 3 480 Asymptomatic, bradycardia for
age
(exon7) c.1032 G> C (p.Ala344¼)b missense variant Pathogenic
5a 11.5 years 4 470 Exercise (exon7) c.940 G> T, c.941 G> T
(p.Gly314Phe)
missense variant Likely
Pathogenic
6a 6.3 years 6 490 Exercise (exon7) c.940G>A (p.Gly314Ser) missense variant Pathogenic
7a 10 years 6.5 623 Exercise (exon7) c.940G>A (p.Gly314Ser) missense variant Pathogenic
KCNH2 mutation (N¼ 5)
8a 6.8 years 5.5 560 Rest (exon 8) c.2086C> T (p.Arg696Cys) missense variant Likely
Pathogenic
9a 0.7 years 5.5 565 Sleep (exon 10) c.2453C>G (p.Ser818Trp) missense variant Likely
Pathogenic
10a 4.2 years 5 557 Sleep c.1882e1884 del (p.Gly628del) Disruptive in-frame
deletion
Likely
Pathogenic
11a 11 years 7 490 Rest c.2327 T> C (p.Leu776Pro) missense variant VUS
12a 8.5 years 6.5 528 Exercise c.1838C> T (p.Thr613Met) missense variant Pathogenic
SCN5A mutation (N¼ 4)
13 10.1 years 6.5 490 Sleep c.715 A>G (p.Ile239Val) missense variant Likely
Pathogenic
14a 12.4 years 5 492 Sleep c.715 A>G (p.Ile239Val) missense variant Likely
Pathogenic
15 7.7 years 5.5 520 Asymptomatic, family
screening
c.715 A>G (p.Ile239Val) missense variant Likely
Pathogenic
16a 1 day 5.5 682 Sleep c.4460 T>A (p.Met1487Lys) missense variant Likely
Pathogenic
Other mutation (N¼ 4)
17a 8.7 years 5.5 565 Sleep ANK2 c.8404 G> C (p.Asp2802His) missense variant VUS
18a 6.7 years 8 510 Exercise Negative e e
19a 9 years 7 731 Rest Negative e e
20a 28 years 5.5 610 Rest Negative e e
QTc¼ corrected QT interval, VUS¼ variants of unknown signiﬁcance.
a Proband.
b Variant is on splice site.
Table 3
Clinical characteristic sub-grouped by rare genetic variants (N¼ 20, 17 families).
Total (N¼ 20) KCNQ1 KCNH2 SCN5A Others Negative
N (%) 7 (35%) 5 (25%)a 4 (20%) 1 (5%)a 3 (15%)
No. of family (%) (Total 17 families) 6 (35%) 5 (29%)a 2 (12%) 1 (6%)a 3 (18%)
Male (%) 3 3 0 1 2
Age at diagnosis (years), Mean (±SD) 5.9 (±4.7) 6.2 (±4) 7.6 (±5.4) 8.7 14.6 (±11.7)
Range 0e11.5 years 0.7e11 years 0e12.4 years e 6.7e28 years
QTc (msec), Mean (±SD) 530 (±56.3) 540 (±31.5) 546 (±91.7) 565 617 (±110.7)
Range 470e623 490e565 490e682 e 510e731
Schwartz's score, Mean (±SD) 4.8 (±1.2) 5.9 (±0.8) 5.6 (±1) 5.5 6.8 (±1.3)
Range 3e6.5 5e7 4.5e6.5 e 5.5e8
Trigger events
Asymptomatic 3 0 1 0 0
Adrenergically mediated cardiac events 4 1 0 0 1
Cardiac events at rest 0 4 3 1 2
a The variant of 1 patient in each group was classiﬁed as VUS (variants of unknown signiﬁcance). The percentage of KCNH2 variants that were pathogenic or likely
pathogenic was 24% with additional 5% had VUS.
A. Saprungruang et al. / Indian Pacing and Electrophysiology Journal 18 (2018) 165e171 167genetic testing at the time of this study. Among the 10 missing
patients, six were lost to follow up (3 patients developed symptoms
during exercise, 2 patients developed symptoms during sleep, and
1 patient was asymptomatic at the time of presentation); and 4
patients had died (3 died shortly after presenting with cardiac ar-
rest during exercise, and 1 presented with aborted sudden cardiac
death during sleep were dead 6.8 years after ICD implantation, he
was lost to follow up for 4.3 years before death). Five out of the 6
patients who were lost to follow up are still alive according to theThai citizen registration record.
Excluding the 10 patients whowere lost to follow-up or died, 20
patients (17 families) were included to this study. The clinical
characteristics of the study subjects are summarized in Table 1.
Nine patients (45%) were male. Their mean age at diagnosis was
7.8± 6.2 years (range 1 daye28 years). Total Schwartz's score was
5.6± 1.2 points (range 3e8 points). All except one patient were
categorized as high probability of LQTS according to Schwartz's
score (score 4 points). Most patients had no co-morbid condition.
Fig. 1. Variation of T wave in a patient with severe presentation of KCNH2 mutation.
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Fig. 2. KaplaneMeier curve demonstrating time to ﬁrst serious cardiac event (death or
ventricular arrhythmia) after diagnosis categorized by genetic mutation (N¼ 20).
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congenital sensorineural hearing loss, and 1 with double aortic
arch. Family history of deﬁnite LQTS was found in 5 (25%), and
family history of cardiac arrest or unexplained sudden cardiac
death was reported in 7 patients (35%).
3.2. Electrocardiographic characteristics
The mean value of the longest QTc interval in each patient was
550.3± 68.8msec (range 470e731 msec). Five patients (25%) had
bradycardia for age. Four patients (20%) presented with torsades de
pointes and/or ventricular ﬁbrillation (TdP/VF). Five patients had
cardiac arrest with no ECG documentation at the time of the arrest.
3.3. Triggers for cardiac events
Patients were divided into 3 groups; 10 patients (50%) devel-
oped cardiac symptoms at rest or sleep, and 6 patients (30%)
developed cardiac events during exercise/stress/startle (adrener-
gically mediated cardiac events). Four patients (20%) were
asymptomatic at presentation; 2 had ECG done for bradycardia and
2 were screened because of family history of LQTS.
3.4. Genetic analysis
Out of the 20 patients screened from 17 families, 15 (12 families)
had pathogenic mutation or likely deleterious (likely pathogenic)
variants in one of the 17 LQTS genes, all in either KCNQ1, KCNH2, or
SCN5A. These were broken down to 6 (35%), 4 (24%) and 2 (12%)
families with KCNQ1, KCNH2 and SCN5A pathogenic or likely path-
ogenic mutations, respectively. All of these variants were not pre-
sent in any of the 719 patients with whole exome study in our in-
house database. Two patients had variants of unknown signiﬁ-
cance (VUS), 1 in KCNH2 and the other in ANK2. In 3 patients, no
pathogenic mutation was found in any of the 17 known LQT genes.
The details of genetic variants and their classiﬁcation are shown in
Table 2.
As for KCNQ1, 6 patients (30%) had pathogenic mutation; 1 pa-
tient (5%) had a likely pathogenic mutation. In this group, two
patients (siblings) with phenotype of Jervell and Lange-Nielsen
syndrome (prolong QT interval and congenital sensorineural
hearing loss) had c.1032 G> C (Homozygous) (p.Ala344¼ ). An
additional 2 unrelated patients with LQTS phenotype also had
c.1032 G> C (p.Ala344¼ , heterozygous). This is a synonymous
variant (no amino acid change), but themutation is located in splice
site which may lead to splice aberration. Two unrelated patient had
pathogenic c.940 G> A mutation (p.Gly314Ser). One patient had
double missense mutation in the same codon (c.940 G> T and
c.941 G> T) (p.Gly314Phe), with no previous report of its patho-
genicity. In silico analysis indicated a deleterious effect of this
variant.
As for KCNH2, 1 patient (5%) had a pathogenic mutation which
was c.1838 C> T variant (p.Thr613Met). Three patients (15%) had
likely pathogenic mutations according to ACMG guideline 2015.
These variants were c.1882e1884 del (p.Gly628del), c.2086 C> T
(p.Arg696Cys) and c.2453 C>G (p.Ser818Trp). One additional pa-
tient had c.2327T> C VUS variant (p.Leu776Pro).
As for SCN5A, 3 siblings in the same family had a likely patho-
genic mutation, c.715 A>G (p.Ile239Val). One additional patient
had c.4460 T> A (p.Met1487Lys), a likely pathogenic mutation,
giving the percentage of families with LQT3 of 12%.
One patient had VUS in ANK2. The variant was c.8404 G> C
(p.Asp2802His) (Class 3 according to ACMG/AMP, 2015 guideline).
There were no identiﬁable rare variants in the 17 known LQTs gene
in 3 patients (18%).3.5. Clinical characteristic sub-grouped by genetic mutation
Average age at presentation, mean of the longest QTc interval,
mean Schwartz's score of each pathogenic or VUS are shown in
Table 3.
In 7 patients with KCNQ1 mutation, 3 were asymptomatic (1
patient presented with fetal bradycardia, 2 with congenital senso-
rineural hearing loss) and 4 developed stress-induced arrhythmia
or syncope.
Most patients with KCNH2 mutation developed symptoms at
rest or sleep, only 1 patient developed symptom during running.
Almost all of our LQTS type 2 patients had severe phenotype (car-
diac arrest) and had ICD implanted. Some of these patients with
severe symptoms demonstrated dynamic changing of T morphol-
ogies with time (Fig. 1). This patient has c.1882e1884 del (p.
Gly628del), which would predict a severe disruption of the protein
subunit of IKr channel.
Three patients with SCN5A mutation developed symptoms at
rest and the other patient was asymptomatic with siblings diag-
nosed with congenital LQTS.3.6. Treatment and follow-up
At the time of this study, the 20 patients have been followed for
a median duration of 5 years (range 0.3e11.7 years). All except one
patients received beta-blocker; either atenolol or propranolol. Nine
patients (45%) were treated with an implantable cardioverter-
deﬁbrillators (ICD); 8 of whom had cardiac events during sleep or
at rest. One patient with SCN5A mutation died suddenly at the age
of 16 years old while she was talking with her siblings. She did not
have an ICD due to lack of symptom and was taking beta-blocker at
the time of death. Her QTc was 492 msec. Her two sisters with
sensorineural hearing loss had cardiac syncope during sitting at the
age of 6.2 and 10.2 years old after non-compliance with beta-
blocker. Additional ﬁve patients had appropriate ICD shock. Sur-
vival from serious cardiac event (death or ventricular arrhythmia)
after diagnosis is showed in Fig. 2.4. Discussion
Most cardiac arrhythmia in congenital long QT syndrome
Table 4
Genotype-Speciﬁc Prevalence of Long QT syndrome in East Asian countries.
Type Gene/
Locus
Japan China Korea Taiwan Present study
Horigome H. et al.,
2010 [7]
Yoshinaga M. et al.,
2014 [20]a
Liu W. et al., 2002
[10]
Gao Y. et al., 2016
[18]
Lee YS. et al., 2013
[19]
Chang YS. et al.,
2015 [11]
17 Families
58 Probands 117 Probands 42 Probands 230 Probands 62 Probands 5 Probands (20 Probands)
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
LQT1 KCNQ1 11 (19%) 35 (30%) 4 (10%) 80 (34.8%) 9 (14.5%) 1 (20%) 6 (35%)
LQT2 KCNH2 11 (19%) 22 (18.8%) 3 (7%) 101 (43.9%) 5 (8.1%) 1 (20%) 4 (24%)
LQT3 SCN5A 6 (10.5%) 17 (14.5%) N/A 5 (2.2%) 3 (4.8%) N/A 2 (12%)
LQT5 KCNE1 N/A 5 (4.3%) N/A N/A N/A N/A 0
LQT6 KCNE2 N/A N/A N/A N/A N/A N/A 0
LQT7 KCNJ2 N/A 2 (1.7%) N/A N/A 3 (4.8%) N/A 0
LQT8 CACNA1C 1 (1.7%) 1 (0.8%) N/A N/A 1 (1.6%) N/A 0
LQT13 KCNJ5 N/A 1 (0.8%) N/A N/A N/A N/A 0
Negative 12 (20.7%) 44 (37.6%) 35 (83%) 44 (19.1%) 21 (33.9%) 3 (60%) 3 (18%)
Others N/A N/A N/A N/A N/A N/A VUS in ANK2 (LQT4)
1 (6%)
KCNH2 1 (6%)
Not test 17 (29.3%) None None None 20 (32.2%) None None
VUS¼ variants of unknown signiﬁcance.
a Multiple mutation in some patients.
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potassium, calcium and sodium channels. Historically, LQTS were
classiﬁed into two groups by the inherited pattern: autosomal
dominant (Romano-Ward syndrome), and autosomal recessive
with neurosensory deafness (Jervell and Lange-Nielsen syndrome).
At present, pathogenic mutation in at least one of the 17 genes
(detailed in Methods section) can be found in 50e80% of all clini-
cally diagnosed LQTS patients [5]. The yield is less in the more
recent cohorts of patient in which patients with less severe phe-
notypes were included [16]. The high yield of genetic testing in our
cohort could be partly explained by the fact that most of our cases
were symptomatic with relatively long QT intervals. Genotypic
classiﬁcation can be used to guide individualized treatment in
these patients [17,18]. The use of clinical presentation, heart rate,
QTc interval, ECG phenotypes, T wave morphology and Schwartz's
score cannot differentiate among the types of LQTS with complete
certainty [19].
Of the 17 genes, most (75%) of the LQTS patients had pathogenic
mutation in only one of the 3 genes: KCNQ1 (30e35%), KCNH2
(25e30%), and SCN5A (5e10%) [20,21]. There are few studies on the
percentage of each type of LQTS in East Asian countries
[8,11,12,22e24], as shown in Table 4. Similar to the Western coun-
tries, the majority of the East Asian patients had LQT1, and LQT2.
From the present study, we found that 18% of our patients had
negative genetic mutation in the known 17 of LQT genes, consistent
with previous reports. As for gene-positive patients, the distribu-
tions of pathogenic or likely pathogenic genetic variants in our
population (using family-based percentage) were 35%, 24%, and
12% in KCNQ1, KCNH2, and SCN5A, respectively. Two patients (12%)
had VUS and 3 (18%) were negative for the known LQT genes var-
iants. Mean age at diagnosis seemed to be lower in LQTS type 1
patients, which is not unexpected as LQT1 patients present with
symptoms at a younger age. The mean QTc was slightly higher in
negative LQT gene mutation in our cohort. Most of the LQT1 pa-
tients developed, as expected, symptoms during exercise and had
typical broad-based prolonged T wave. Both patients with Jervell
and Lange-Nielsen syndrome in our study were asymptomatic and
were presented with bilateral congenital sensorineural hearing
loss. Most of the LQT2 patients developed symptoms during sleep
or rest and had biﬁd T wave, and almost all had previous history of
cardiac arrest, indicating more severe phenotype than LQT1 pa-
tients in our population.4.1. Study limitations
Our study was based on patients who presented to the hospital,
which likely represent only the most severe cases of LQTS patients
[16]. Moreover, we still lack an appropriate screening program for
family members of genotype positive patients so the patients who
were asymptomatic might not have come to medical attention and
long QT syndrome might still be under recognized in Thailand.
Further genetic testing in family members should be provided to
identify those family members with pre-symptomatic congenital
long QT syndrome.
5. Conclusions
Our study is the ﬁrst to report prevalence of genetic mutations,
and demonstrate phenotype-genotype characteristics in congenital
long QT syndrome patients in Thailand. Seventy-one percent of the
LQTS families can be classiﬁed as LQT1, 2 or 3.
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